Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ocugen, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
OCGN
Nasdaq
2836
www.ocugen.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ocugen, Inc.
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
- Feb 3rd, 2025 11:30 am
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
- Jan 27th, 2025 11:30 am
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
- Jan 17th, 2025 10:31 am
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
- Jan 16th, 2025 12:30 pm
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
- Jan 13th, 2025 11:30 am
5 Biotech Breakthrough Stocks to Watch in 2025
- Dec 23rd, 2024 2:39 pm
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Dec 19th, 2024 11:38 am
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
- Dec 11th, 2024 12:02 pm
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
- Nov 27th, 2024 12:09 pm
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
- Nov 20th, 2024 12:30 pm
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Nov 19th, 2024 12:02 pm
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
- Nov 14th, 2024 9:40 pm
Ocugen: Q3 Earnings Snapshot
- Nov 14th, 2024 8:32 pm
Q3 2024 Ocugen Inc Earnings Call
- Nov 9th, 2024 7:14 am
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
- Nov 9th, 2024 7:05 am
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
- Nov 8th, 2024 4:15 pm
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
- Nov 8th, 2024 11:45 am
Ocugen Secures $30 Million in Debt Funding
- Nov 7th, 2024 11:30 am
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%
- Oct 31st, 2024 2:56 pm
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
- Oct 28th, 2024 10:30 am
Scroll